GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
GLP-1s in CKD: Evidence, market leadership, and key insights from ASN 2025 At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with more than 70 sessions, posters, and oral abstracts probing their role across the kidney-disease continuum, and even a dedicated mention during the opening plenary talk
Sun H, Shu J, Tang J, et al
Brain fog often stems from inflammation, poor gut health, mitochondrial dysfunction, and metabolic issues
Coverage is limited to patients who meet specific clinical criteria and receive approval through the prior authorization process
The SURMOUNT-5 results are not surprising, said Avlin Imaeda, MD, PhD, associate professor of digestive diseases and medical director of the North Haven Endoscopy Center at Yale School of Medicine